The Prostate最新文献

筛选
英文 中文
Three‐dimensional ultrastructural and anatomical analysis of prostatic neuroendocrine cells in mice 小鼠前列腺神经内分泌细胞的三维超微结构和解剖分析
The Prostate Pub Date : 2024-04-09 DOI: 10.1002/pros.24705
Kei‐Ichiro Uemura, Akinobu Togo, Tasuku Hiroshige, Keisuke Ohta, Kosuke Ueda, Kiyoaki Nishihara, Makoto Nakiri, Shingo Hirashima, Tsukasa Igawa, Kei‐Ichiro Nakamura
{"title":"Three‐dimensional ultrastructural and anatomical analysis of prostatic neuroendocrine cells in mice","authors":"Kei‐Ichiro Uemura, Akinobu Togo, Tasuku Hiroshige, Keisuke Ohta, Kosuke Ueda, Kiyoaki Nishihara, Makoto Nakiri, Shingo Hirashima, Tsukasa Igawa, Kei‐Ichiro Nakamura","doi":"10.1002/pros.24705","DOIUrl":"https://doi.org/10.1002/pros.24705","url":null,"abstract":"BackgroundA few studies have examined the ultrastructure of prostatic neuroendocrine cells (NECs), and no study has focused on their ultrastructure in three dimensions. In this study, three‐dimensional ultrastructural analysis of mouse prostatic NECs was performed to clarify their anatomical characteristics.MethodsThree 13‐week‐old male C57BL/6 mice were deeply anesthetized, perfused with physiological saline and 2% paraformaldehyde, and then placed in 2.5% glutaraldehyde in 0.1 M cacodylate (pH 7.3) buffer for electron microscopy. After perfusion, the lower urinary tract, which included the bladder, prostate, coagulation gland, seminal vesicle, upper vas deferens, and urethra, was removed, and the specimen was cut into small cubes and subjected to postfixation and en bloc staining. Three‐dimensional ultrastructural analysis was performed on NECs, the surrounding cells, tissues, and nerves using focused ion beam/scanning electron microscope tomography.ResultsTwenty‐seven serial sections were used in the present study, and 32 mouse prostatic NECs were analyzed. Morphologically, the NECs could be classified into three types: flask, flat, and closed. Closed‐shaped NECs were always adjacent to flask‐shaped cells. The flask‐shaped and flat NECs were in direct contact with the ductal lumen and always had microvilli at their contact points. Many of the NECs had accompanying nerves, some of which terminated on the surface in contact with the NEC.ConclusionsThree‐dimensional ultrastructural analysis of mouse prostatic NECs was performed. These cells can be classified into three types based on shape. Novel findings include the presence of microvilli at their points of contact with the ductal lumen and the presence of accompanying nerves.","PeriodicalId":501684,"journal":{"name":"The Prostate","volume":"57 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140593134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in whole blood 开发全血前列腺癌多基因组液体活检(PROSTest)
The Prostate Pub Date : 2024-04-04 DOI: 10.1002/pros.24704
Irvin M. Modlin, Mark Kidd, Ignat A. Drozdov, Martin Boegemann, Lisa Bodei, Jolanta Kunikowska, Anna Malczewska, Christof Bernemann, Srinivas V. Koduru, Kambiz Rahbar
{"title":"Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in whole blood","authors":"Irvin M. Modlin, Mark Kidd, Ignat A. Drozdov, Martin Boegemann, Lisa Bodei, Jolanta Kunikowska, Anna Malczewska, Christof Bernemann, Srinivas V. Koduru, Kambiz Rahbar","doi":"10.1002/pros.24704","DOIUrl":"https://doi.org/10.1002/pros.24704","url":null,"abstract":"IntroductionWe describe the development of a molecular assay from publicly available tumor tissue mRNA databases using machine learning and present preliminary evidence of functionality as a diagnostic and monitoring tool for prostate cancer (PCa) in whole blood.Materials and MethodsWe assessed 1055 PCas (public microarray data sets) to identify putative mRNA biomarkers. Specificity was confirmed against 32 different solid and hematological cancers from The Cancer Genome Atlas (<jats:italic>n</jats:italic> = 10,990). This defined a 27‐gene panel which was validated by qPCR in 50 histologically confirmed PCa surgical specimens and matched blood. An ensemble classifier (Random Forest, Support Vector Machines, XGBoost) was trained in age‐matched PCas (<jats:italic>n</jats:italic> = 294), and in 72 controls and 64 BPH. Classifier performance was validated in two independent sets (<jats:italic>n</jats:italic> = 263 PCas; <jats:italic>n</jats:italic> = 99 controls). We assessed the panel as a postoperative disease monitor in a radical prostatectomy cohort (RPC: <jats:italic>n</jats:italic> = 47).ResultsA PCa‐specific 27‐gene panel was identified. Matched blood and tumor gene expression levels were concordant (<jats:italic>r</jats:italic> = 0.72, <jats:italic>p</jats:italic> &lt; 0.0001). The ensemble classifier (“PROSTest”) was scaled 0%–100% and the industry‐standard operating point of ≥50% used to define a PCa. Using this, the PROSTest exhibited an 85% sensitivity and 95% specificity for PCa versus controls. In two independent sets, the metrics were 92%–95% sensitivity and 100% specificity. In the RPCs (<jats:italic>n</jats:italic> = 47), PROSTest scores decreased from 72% ± 7% to 33% ± 16% (<jats:italic>p</jats:italic> &lt; 0.0001, Mann–Whitney test). PROSTest was 26% ± 8% in 37 with normal postoperative PSA levels (&lt;0.1 ng/mL). In 10 with elevated postoperative PSA, PROSTest was 60% ± 4%.ConclusionA 27‐gene whole blood signature for PCa is concordant with tissue mRNA levels. Measuring blood expression provides a minimally invasive genomic tool that may facilitate prostate cancer management.","PeriodicalId":501684,"journal":{"name":"The Prostate","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140593338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ten‐year functional and oncological outcomes of a prospective randomized controlled trial comparing laparoscopic versus robot‐assisted radical prostatectomy 比较腹腔镜与机器人辅助前列腺癌根治术的前瞻性随机对照试验的十年功能和肿瘤学结果
The Prostate Pub Date : 2024-04-04 DOI: 10.1002/pros.24702
Enrico Checcucci, Sabrina De Cillis, Eugenio Alladio, Federico Piramide, Gabriele Volpi, Stefano Granato, Davide Zamengo, Gabriele Bignante, Daniele Amparore, Alberto Piana, Matteo Manfredi, Edoardo Vallariello, Ilaria Stura, Michele Di Dio, Riccardo Autorino, Francesco Porpiglia, Cristian Fiori
{"title":"Ten‐year functional and oncological outcomes of a prospective randomized controlled trial comparing laparoscopic versus robot‐assisted radical prostatectomy","authors":"Enrico Checcucci, Sabrina De Cillis, Eugenio Alladio, Federico Piramide, Gabriele Volpi, Stefano Granato, Davide Zamengo, Gabriele Bignante, Daniele Amparore, Alberto Piana, Matteo Manfredi, Edoardo Vallariello, Ilaria Stura, Michele Di Dio, Riccardo Autorino, Francesco Porpiglia, Cristian Fiori","doi":"10.1002/pros.24702","DOIUrl":"https://doi.org/10.1002/pros.24702","url":null,"abstract":"BackgroundAmong prostate cancer (PCa) treatment options, mini‐invasive surgical approaches have gained a wide diffusion in the last decades. The aim of this study was to present oncological, functional, and quality of life data after 10 years of follow‐up of a prospective randomized controlled trial (RCT) (ISRCTN11552140) comparing robot‐assisted radical prostatectomy (RARP) versus laparoscopic radical prostatectomy (LRP) for the treatment of PCa.MethodsPatients with localized PCa were randomized to undergo LRP or RARP between January 2010 and January 2011. Functional (continence and potency) and oncological (prostate‐specific antigen, biochemical recurrence [BCR] and BCR‐free survival [BCRFS]) variables were evaluated. BCRFS curves were estimated by the Kaplan–Meier method and compared using the log‐rank test. Machine learning partial least square‐discriminant analysis (PLS‐DA) was used to identify the variables characterizing more the patients who underwent RARP or LRP.ResultsSeventy‐five of the originally enrolled 120 patients remained on follow‐up for 10 years; 40 (53%) underwent RARP and 35 (47%) LRP. Continence and potency recovery rates did not show significant differences (<jats:italic>p</jats:italic> = 0.068 and <jats:italic>p</jats:italic> = 0.56, respectively), despite a Δ12% for continence and Δ8% for potency in favor of the robotic approach. However, the quality of continence (in terms of International Consultation on Incontinence Questionnaire‐Short Form [ICIQ‐SF] score) and erection (in terms of International Index of Erectile Function‐5 [IIEF‐5] score) was significantly better after 10 years in the robotic group (<jats:italic>p</jats:italic> = 0.02 and <jats:italic>p</jats:italic> &lt; 0.001). PLS‐DA revealed that LRP was characterized by the worst functional‐related outcomes analyzing the entire follow‐up period. Four (10%) and six (17%) patients experienced BCR in RARP and LRP groups, respectively (<jats:italic>p</jats:italic> = 0.36), with an overall 10‐year BCR‐free survival of 88% and 78% (<jats:italic>p</jats:italic> = 0.16).ConclusionsComparable continence and potency rates were observed between RARP and LRP after a 10‐year follow‐up. However, the RARP group exhibited superior totally dry rate and erection quality. No difference in terms of oncological outcomes was found.","PeriodicalId":501684,"journal":{"name":"The Prostate","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140592908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and validation of an imageless machine‐learning algorithm for the initial screening of prostate cancer 开发和验证用于前列腺癌初步筛查的无图像机器学习算法
The Prostate Pub Date : 2024-04-04 DOI: 10.1002/pros.24703
Nicolas Martelin, Brian De Witt, Benjamin Chen, Pascal Eschwège
{"title":"Development and validation of an imageless machine‐learning algorithm for the initial screening of prostate cancer","authors":"Nicolas Martelin, Brian De Witt, Benjamin Chen, Pascal Eschwège","doi":"10.1002/pros.24703","DOIUrl":"https://doi.org/10.1002/pros.24703","url":null,"abstract":"PurposeProstate specific antigen (PSA) testing is a low‐cost screening method for prostate cancer (PCa). However, its accuracy is limited. While progress is being made using medical imaging for PCa screening, PSA testing can still be improved as an easily accessible first step in the screening process. We aimed to develop and validate a new model by further personalizing the analysis of PSA with demographic, medical history, lifestyle parameters, and digital rectal examination (DRE) results.MethodsUsing data from 34,224 patients in the screening arm of the PLCO trial (22,188 for the training set and 12,036 for the validation set), we applied a gradient‐boosting model whose features (Model 1) were one PSA value and the personal variables available in the PLCO trial except those that signaled an ex‐ante assumption of PCa. A second algorithm (Model 2) included a DRE result. The primary outcome was the occurrence of PCa, while the aggressiveness of PCa was a secondary outcome. ROC analyses were used to compare both models to other initial screening tests.ResultsThe areas under the curve (AUC) for Model 2 was 0.894 overall and 0.908 for patients with a suspicious DRE, compared to 0.808 for PSA for patients with a suspicious DRE. The AUC for Model 1 was 0.814 compared to 0.821 for PSA. Model 2 predicted 58% more high‐risk PCa than PSA ≥4 combined with an abnormal DRE and had a positive predictive value of 74.7% (vs. 50.6%).ConclusionPersonalizing the interpretation of PSA values and DRE results with a gradient‐boosting model showed promising results as a potential novel, low‐cost method for the initial screening of PCa. The importance of DRE, when included in such a model, was also highlighted.","PeriodicalId":501684,"journal":{"name":"The Prostate","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140592918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A pooled patient-reported outcomes analysis of moderately hypofractionated proton beam therapy and photon-based intensity modulated radiation therapy for low- or intermediate-risk prostate cancer 中度低分次质子束疗法和光子调强放射疗法治疗低危或中危前列腺癌的患者报告结果汇总分析
The Prostate Pub Date : 2023-12-18 DOI: 10.1002/pros.24660
Alexander Lukez, Elizabeth Handorf, Nancy P. Mendenhall, Randal H. Henderson, Bradley J. Stish, Brian J. Davis, Mark Hallman, Eric M. Horwitz, Neha Vapiwala, Jessica Karen Wong
{"title":"A pooled patient-reported outcomes analysis of moderately hypofractionated proton beam therapy and photon-based intensity modulated radiation therapy for low- or intermediate-risk prostate cancer","authors":"Alexander Lukez, Elizabeth Handorf, Nancy P. Mendenhall, Randal H. Henderson, Bradley J. Stish, Brian J. Davis, Mark Hallman, Eric M. Horwitz, Neha Vapiwala, Jessica Karen Wong","doi":"10.1002/pros.24660","DOIUrl":"https://doi.org/10.1002/pros.24660","url":null,"abstract":"We sought to characterize and compare late patient-reported outcomes (PROs) after moderately hypofractionated intensity modulated radiation therapy (IMRT) and proton beam therapy (PBT) for localized prostate cancer (PC).","PeriodicalId":501684,"journal":{"name":"The Prostate","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138716178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer 以谷氨酰胺依赖性为靶点的 DRP-104 可抑制耐阉割前列腺癌的增殖和肿瘤生长
The Prostate Pub Date : 2023-12-12 DOI: 10.1002/pros.24654
David Moon, J. Spencer Hauck, Xue Jiang, Holly Quang, Lingfan Xu, Fan Zhang, Xia Gao, Robert Wild, Jeffrey I. Everitt, Everardo Macias, Yiping He, Jiaoti Huang
{"title":"Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer","authors":"David Moon, J. Spencer Hauck, Xue Jiang, Holly Quang, Lingfan Xu, Fan Zhang, Xia Gao, Robert Wild, Jeffrey I. Everitt, Everardo Macias, Yiping He, Jiaoti Huang","doi":"10.1002/pros.24654","DOIUrl":"https://doi.org/10.1002/pros.24654","url":null,"abstract":"Prostate cancer (PCa) continues to be one of the leading causes of cancer deaths in men. While androgen deprivation therapy is initially effective, castration-resistant PCa (CRPC) often recurs and has limited treatment options. Our previous study identified glutamine metabolism to be critical for CRPC growth. The glutamine antagonist 6-diazo-5-oxo-<span>l</span>-norleucine (DON) blocks both carbon and nitrogen pathways but has dose-limiting toxicity. The prodrug DRP-104 is expected to be preferentially converted to DON in tumor cells to inhibit glutamine utilization with minimal toxicity. However, CRPC cells' susceptibility to DRP-104 remains unclear.","PeriodicalId":501684,"journal":{"name":"The Prostate","volume":"173 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138577410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
4-Octyl itaconate alleviates experimental autoimmune prostatitis by inhibiting the NLRP3 inflammasome-induced pyroptosis through activating Nrf2/HO-1 pathway 伊它康酸 4-辛酯通过激活 Nrf2/HO-1 通路抑制 NLRP3 炎症体诱导的热蛋白沉积,从而减轻实验性自身免疫性前列腺炎的病情
The Prostate Pub Date : 2023-12-10 DOI: 10.1002/pros.24652
Xiaohu Zhao, Rui Feng, Juan Chen, Qing Jiang, Xiaoliang Hua, Chaozhao Liang
{"title":"4-Octyl itaconate alleviates experimental autoimmune prostatitis by inhibiting the NLRP3 inflammasome-induced pyroptosis through activating Nrf2/HO-1 pathway","authors":"Xiaohu Zhao, Rui Feng, Juan Chen, Qing Jiang, Xiaoliang Hua, Chaozhao Liang","doi":"10.1002/pros.24652","DOIUrl":"https://doi.org/10.1002/pros.24652","url":null,"abstract":"Chronic prostatitis demonstrates a prevalence rate of nearly 5%–10% among young and middle-aged individuals, significantly affecting their daily lives. Researchers have obtained significant outcomes investigating the anti-inflammatory properties of itaconic acid (IA) and its derivative, 4-Octyl itaconate (4-OI), against diverse chronic inflammatory disorders, such as osteoarthritis and airway inflammation. Nevertheless, whether IA can also exert anti-inflammatory effects in chronic prostatitis requires extensive research and validation.","PeriodicalId":501684,"journal":{"name":"The Prostate","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138577411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prostate cancer grade downgrading at time of prostatectomy provides risk-stratification insight into future tumor behavior after prostatectomy. 前列腺切除术时前列腺癌等级的降低为前列腺切除术后未来肿瘤行为提供了风险分层的见解。
IF 2.8
The Prostate Pub Date : 2022-12-01 Epub Date: 2022-08-03 DOI: 10.1002/pros.24425
Shu Wang, J Ryan Russell, Max Drescher, Ashley Park, Teklu Legesse, Vikas Kundra, Phuoc T Tran, Michael Phelan, Michael Naslund, M Minhaj Siddiqui
{"title":"Prostate cancer grade downgrading at time of prostatectomy provides risk-stratification insight into future tumor behavior after prostatectomy.","authors":"Shu Wang,&nbsp;J Ryan Russell,&nbsp;Max Drescher,&nbsp;Ashley Park,&nbsp;Teklu Legesse,&nbsp;Vikas Kundra,&nbsp;Phuoc T Tran,&nbsp;Michael Phelan,&nbsp;Michael Naslund,&nbsp;M Minhaj Siddiqui","doi":"10.1002/pros.24425","DOIUrl":"https://doi.org/10.1002/pros.24425","url":null,"abstract":"<p><strong>Background: </strong>Prostate biopsy (Bx) sampling-based diagnosis of prostate cancer (PCa) has well-described inaccuracy when compared against whole gland analysis upon prostatectomy. Although upgrading of PCa Grade Group (GG) is often described, the occurrence and prognostic implications of downgrading PCa GG at the time of radical prostatectomy (RP) is less understood. Our objective was to evaluate whether downgrading PCa GG at the time of RP was associated with future tumor behavior.</p><p><strong>Methods: </strong>The SEER database was searched from 2010 to 2017 and patients were included if they were assigned pathological grades on both Bx and RP specimen. Patients were stratified into Bx GG > RP GG and Bx GG ≤ RP GG groups, and tumor behavior after treatment was examined. Cox regression was used for the survival analysis.</p><p><strong>Results: </strong>Here, 99,835 patients were included in this study. A total of 18,516 (18.5%) patients encountered downgrading from Bx GG to RP GG. A downgrading of 1 grade occurred in 13,969 (75.4%) of these patients and of 2 or more grades occurred in 4547 (24.6%) patients. A history of higher Bx GG compared with RP GG increased the risk of cancer-specific mortality (CSM) for each given RP GG controlling for age, race, preop prostate-specific antigen level, percentage of positive biopsy cores, and pathologic TNM stages. Specifically, a history of high Bx GG conferred a 45% increased risk of CSM for any given RP GG (hazard ratio = 1.45 95% confidence interval = 1.16-1.82, p < 0.001).</p><p><strong>Conclusion: </strong>A history of higher Bx GG, and hence downgrading at the time of RP, demonstrates some value as a risk-stratification tool for future cancer outcomes after prostatectomy.</p>","PeriodicalId":501684,"journal":{"name":"The Prostate","volume":" ","pages":"1520-1528"},"PeriodicalIF":2.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40668681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
CD47 (don't eat me signal) expression levels and its relationship with clinicopathologic features in early-stage prostate carcinoma. 早期前列腺癌中CD47(不要吃我信号)表达水平及其与临床病理特征的关系
IF 2.8
The Prostate Pub Date : 2022-12-01 Epub Date: 2022-08-28 DOI: 10.1002/pros.24432
Hüseyin S Semiz, Ülkü Küçük, Erdem Kısa, Merve Keskinkılıç, Dilara Ecem Süyün, Mehmet Emin Arayıcı, Elif Atağ, Aziz Karaoglu
{"title":"CD47 (don't eat me signal) expression levels and its relationship with clinicopathologic features in early-stage prostate carcinoma.","authors":"Hüseyin S Semiz,&nbsp;Ülkü Küçük,&nbsp;Erdem Kısa,&nbsp;Merve Keskinkılıç,&nbsp;Dilara Ecem Süyün,&nbsp;Mehmet Emin Arayıcı,&nbsp;Elif Atağ,&nbsp;Aziz Karaoglu","doi":"10.1002/pros.24432","DOIUrl":"https://doi.org/10.1002/pros.24432","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer is a cancer with poor host immune response and could be defined as a non-T-cell inflamed tumor. Therefore, immunotherapy treatments could not be included in the treatment of prostate cancer until recently. Inadequate antitumoral response is one of the main reasons why tumor cells multiply rapidly and cause lethal results. It was shown that CD47 molecule, which is secreted at high levels by leukemia cells, reduces macrophage-mediated phagocytosis and thus facilitates escape from the antitumoral immune response. The aim of this study was to show don't eat me signaling in prostate carcinoma tissues and its relationship with macrophage polarization.</p><p><strong>Materials and methods: </strong>A total of 263 patients with a diagnosis of prostatic adenocarcinoma after radical prostatectomy between 2015 and 2020 at our institute were included in the study. CD47, CD68, and CD163 expression levels were examined immunohistochemically (IHC) in these tissues. The relationship of these expression levels with unfavorable prognostic factors and survival for prostate carcinoma was investigated.</p><p><strong>Results: </strong>In this study, all the operated prostate carcinoma cases had CD47 expression in tumor tissue, but only 52.5% had a high level of expression. Of 263 prostate cancer tissues, 135 (51.3%) showed high expression of CD68 protein and 189 (71.9%) showed high expression of CD163 protein. There was a statistically strong relationship between CD47, CD68, and CD163.</p><p><strong>Conclusions: </strong>The CD47 molecule is basically a molecule that inhibits macrophage activation. CD68 is mostly used for macrophage classification, while CD163 is used for tumor-associated macrophage classification. Unlike others, we IHC examined CD47, CD68, and CD163 expressions in the surgical materials of patients who were operated for prostate carcinoma. In addition, we concluded that strong CD47 expression was closely associated with strong CD68 and CD163 expression in all tumor samples. However, a significant relationship between these expression levels and survival could not be demonstrated.</p>","PeriodicalId":501684,"journal":{"name":"The Prostate","volume":" ","pages":"1564-1571"},"PeriodicalIF":2.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33441435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Differential effects of omega-3 PUFAS on tumor progression at early and advanced stages in TRAMP mice. omega-3 PUFAS对TRAMP小鼠早期和晚期肿瘤进展的不同影响。
IF 2.8
The Prostate Pub Date : 2022-12-01 Epub Date: 2022-08-29 DOI: 10.1002/pros.24421
Gustavo M Amaro, Alana D T da Silva, Guilherme H Tamarindo, Celina de A Lamas, Sebastião R Taboga, Valéria Helena Alves Cagnon, Rejane M Góes
{"title":"Differential effects of omega-3 PUFAS on tumor progression at early and advanced stages in TRAMP mice.","authors":"Gustavo M Amaro,&nbsp;Alana D T da Silva,&nbsp;Guilherme H Tamarindo,&nbsp;Celina de A Lamas,&nbsp;Sebastião R Taboga,&nbsp;Valéria Helena Alves Cagnon,&nbsp;Rejane M Góes","doi":"10.1002/pros.24421","DOIUrl":"https://doi.org/10.1002/pros.24421","url":null,"abstract":"<p><strong>Background: </strong>In vitro studies evidenced antitumor effects of omega-3 polyunsaturated fatty acids ([n-3] PUFAs), but their effects on prostate cancer (PCa) remain controversial in epidemiological studies. Here we investigated whether an (n-3) PUFA-enriched diet affects tumor progression in transgenic adenocarcinoma of the mouse prostate (TRAMP), at early (12 weeks age) and advanced stages (20 weeks age).</p><p><strong>Methods: </strong>TRAMP mice were fed with standard rodent diet (C12, C20) or (n-3) PUFA-enriched diet containing 10% fish oil (T12, T20). A group of 8 weeks age animals fed standard diet was also used for comparison (C8). The ventral prostate was processed for histopathological and immunohistochemical analyses and serum samples submitted to biochemical assays.</p><p><strong>Results: </strong>At early stages, (n-3) PUFA increased the frequency of normal epithelium (3.8-fold) and decreased the frequency of high-grade intraepithelial neoplasia (3.3-fold) and in situ carcinoma (1.9-fold) in the gland, maintaining prostate pathological status similar to C8 group. At advanced stages, 50% of the animals developed a large primary tumor in both C20 and T20, and tumor weight did not differ (C20: 2.2 ± 2.4; T20: 2.8 ± 2.9 g). The ventral prostate of T12 and of T20 animals that did not develop primary tumors showed lower cell proliferation, tissue expressions of androgen (AR) and glucocorticoid (GR) receptors, than their respective controls. For these animals, (n-3) PUFA also avoided an increase in the number of T-lymphocytes, collagen fibers, and αSMA immunoreactivity, and preserved stromal gland microenvironment. (n-3) PUFA also lowered serum triglycerides and cholesterol, regulating the lipid metabolism of TRAMP mice.</p><p><strong>Conclusions: </strong>(n-3) PUFAs had a protective effect at early stages of PCa, delaying tumor progression in TRAMP mice, in parallel with reductions in cell proliferation, AR, and GR and maintenance of the stromal compartment of the gland. However, (n-3) PUFAs did not prevent the development of primary tumors for the T20 group, reinforcing the need for further investigation at advanced stages of disease.</p>","PeriodicalId":501684,"journal":{"name":"The Prostate","volume":" ","pages":"1491-1504"},"PeriodicalIF":2.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33446846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信